Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus

Endocrine Journal

Volumn 60, Issue 3, 2013, Pages 347-357

  Hu, Jianxia ^a   Yu, Xiaolong ^a   Wang, Zhongchao ^a   Wang, Fang ^a   Wang, Li ^a   Gao, Hong ^a   Chen, Ying ^a   Zhao, Wenjuan ^a   Jia, Zhaotong ^a   Yan, Shengli ^a   Wang, Yangang ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Implantation; Mesenchymal stem cell; Type 1 diabetes; Umbilical cord

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEWLY ONSET TYPE 1 DIABETES MELLITUS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME; WHARTON JELLY;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; POSTPRANDIAL PERIOD; UMBILICAL CORD; WHARTON JELLY; YOUNG ADULT;

EID: 84875876271     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0343     Document Type: Article

References (41)

1. Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293-1300.
2. Ashcroft FM, Rorsman P (2012) Diabetes mellitus and the β cell: the last ten years. Cell 148: 1160-1171.
3. Jensen RA, Agardh E, Lernmark A, Gudbjörnsdottir S, Smith NL, et al. (2011) HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later. PLoS One 6:e17569.
4. Rabinovitch A (1994) Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 43:613-621.
5. Basford CL, Prentice KJ, Hardy AB, Sarangi F, Micallef SJ, et al. (2012) The functional and molecular characterisation of human embryonic stem cell-derived insulinpositive cells compared with adult pancreatic beta cells. Diabetologia 55:358-371
6. Koblas T, Zacharovová K, Berková Z, Leontovic I, Dovolilová E, et al. (2009) In vivo differentiation of human umbilical cord blood-derived cells into insulinproducing beta cells. Folia Biol (Praha) 55:224-232.
7. Kunisada Y, Tsubooka-Yamazoe N, Shoji M, Hosoya M (2012) Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells. Stem Cell Res 8:274-284.
8. Wang HS, Shyu JF, Shen WS, Hsu HC, Chi TC, et al. (2011) Transplantation of insulin- producing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice. Cell Transplant 20:455-466.
9. Shi Y, Hu G, Su J, Li W, Chen Q, et al. (2010) Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20:510-518.
10. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, et al. (2010) Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 19:667-679.
11. Sioud M (2011) New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol 73:79-84.
12. Zhou H, Guo M, Bian C, Sun Z, Yang Z, et al. (2010) Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graftversus-host disease: clinical report. Biol Blood Marrow Transplant 16:403-412.
13. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, et al. (2011) Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graftversus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17:534-541.
14. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, et al. (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67:1187-1194.
15. Liang J, Zhang H, Hua B, Wang H, Lu L, et al. (2010) Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 69:1423-1429.
16. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, et al. (2010) Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59:1662-1669.
17. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, et al. (2009) Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183:993-1004.
18. Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, et al. (2009) Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52:1391-1399.
19. Zanone MM, Favaro E, Miceli I, Grassi G, Camussi E, et al. (2010) Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes. J Clin Endocrinol Metab 95:3788-3797.
20. Bai J, Hu Y, Wang YR, Liu LF, Chen J, et al. (2012) Comparison of human amniotic fluid-derived and umbilical cord Wharton's Jelly-derived mesenchymal stromal cells: Characterization and myocardial differentiation capacity. J Geriatr Cardiol 9:166-171.
21. Poloni A, Maurizi G, Serrani F, Mancini S, Discepoli G, et al. (2012) Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate. Cell Prolif 45:66-75.
22. Mazzini L, Mareschi K, Ferrero I, Miglioretti M, Stecco A, et al. (2012) Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy 14:56-60.
23. Weil BR, Herrmann JL, Abarbanell AM, Manukyan MC, Poynter JA, et al. (2011) Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia. Shock 36:235-241.
24. Hannoush EJ, Sifri ZC, Elhassan IO, Mohr AM, Alzate WD, et al. (2011) Impact of enhanced mobilization of bone marrow derived cells to site of injury. J Trauma 71:283-289.
25. Anzalone R, Lo Iacono M, Loria T, Di Stefano A, Giannuzzi P, et al. (2011) Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev 7:342-363.
26. Tsai PJ, Wang HS, Shyr YM, Weng ZC, Tai LC, et al. (2012) Transplantation of insulin- producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats. J Biomed Sci 19:47.
27. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, et al. (2011) Co- transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 54:1127-1135.
28. Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, et al. (2011) Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 46:562-566.
29. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, et al. (2007) Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297:1568-1576.
30. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, et al. (2009) C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301:1573-1579.
31. Mabed M, Shahin M (2012) Mesenchymal stem cellbased therapy for the treatment of type 1 diabetes mellitus. Curr Stem Cell Res Ther 7:179-190.
32. De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, et al. (2012) Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 12:574-591.
33. Kim SJ, Choi YS, Ko ES, Lim SM, Lee CW, et al. (2012) Glucose-stimulated insulin secretion of various mesenchymal stem cells after insulin-producing cell differentiation. J Biosci Bioeng 113:771-777.
34. Lin P, Chen L, Li D, Yang N, Sun Y, et al. (2009) Dynamic analysis of bone marrow mesenchymal stem cells migrating to pancreatic islets using coculture microfluidic chips: An accelerated migrating rate and better survival of pancreatic islets were revealed. Neuro Endocrinol Lett 30:204-208.
35. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, et al. (2006) Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 103:17438-17443.
36. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, et al. (2005) Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106:419-427.
37. Bell GI, Broughton HC, Levac KD, Allan DA, Xenocostas A, et al. (2012) Transplanted human bone marrow progenitor subtypes stimulate endogenous islet regeneration and revascularization. Stem Cells Dev 21:97-109.
38. Lu Y, Jin X, Chen Y, Li S, Yuan Y, et al. (2010) Mesenchymal stem cells protect islets from hypoxia/ reoxygenation-induced injury. Cell Biochem Funct 28:637-643.
39. Vilalta M, Dégano IR, Bagó J, Gould D, Santos M, et al. (2008) Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity noninvasive bioluminescence imaging. Stem Cells Dev 17: 993-1003.
40. Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, et al. (2011) Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J 58:869-877.
41. Hassan K, Heptulla RA (2009) Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. Pediatr Diabetes 10:264-268.